Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5591-5600 Newer>

The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
The Motley Fool April 24, 2009 Brian Orelli	Just Say No to "Say on Pay"? For all the complaining that investors and analysts do about executive pay, it might come as a surprise that investors rejected two out of the three "say on pay" proposals at pharmaceutical companies' annual meetings.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool April 24, 2009 Brian Orelli	Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters.
BusinessWeek April 23, 2009 Keith Epstein	Newt Gingrich's Health-Care Mission Newt Gingrich's for-profit company is advising clients such as IBM how to grab some of the $19 billion in funds earmarked for digitizing health-care records.
BusinessWeek April 23, 2009 Catherine Arnst	Doctors' Pride: A Hurdle to Digital Medicine A forerunner in New England found that some physicians would sooner cut ties than see their elite status threatened.
The Motley Fool April 23, 2009 Tim Beyers	Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? Take a look at: Charming Shoppes... Hansen Medical... Suffolk Bancorp... Greenbrier Companies... Valeant Pharmaceuticals...
The Motley Fool April 23, 2009 Brian Orelli	Hitting the Patent Cliff Early Glaxo is at the front edge of a patent cliff. But that means that when other drugmakers are hurting a few years down the road, Glaxo should be sitting pretty, seeing the fruits of all those partnerships it's investing in now.
<Older 5591-5600 Newer> Return to current articles.